{"id":109442,"date":"2026-06-16T21:20:15","date_gmt":"2026-06-16T21:20:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/109442\/"},"modified":"2026-06-16T21:20:15","modified_gmt":"2026-06-16T21:20:15","slug":"novo-nordisk-cpsenovo-b-prepares-china-filing-for-oral-wegovy-pill","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/109442\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Prepares China Filing For Oral Wegovy Pill"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.<\/p>\n

Novo Nordisk (CPSE:NOVO B) plans to seek Chinese regulatory approval for its oral Wegovy obesity pill.<\/p>\n

The planned filing would extend the company’s weight loss franchise into China, a large potential market for obesity therapies.<\/p>\n

This move comes after prior focus on injectable Wegovy and recent attention on regulatory milestones in other regions, including the UK.<\/p>\n

Novo Nordisk, best known for its diabetes and obesity treatments, is pushing further into weight management with the oral version of Wegovy. The decision to prepare a filing in China signals how central obesity therapy has become to the company alongside its traditional diabetes business. Investors tracking CPSE:NOVO B are paying close attention to how oral treatments might broaden access compared with injections in markets with large populations.<\/p>\n

This potential China submission also comes at a time when competition with Eli Lilly in obesity drugs is intensifying. Regulatory progress, timelines, and any label specifics in China are likely to be key focus points for investors watching the next phase of Novo Nordisk’s obesity strategy.<\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk.<\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B Earnings & Revenue Growth as at Jun 2026 <\/p>\n

3 things going right for Novo Nordisk that this headline doesn’t cover.<\/a><\/p>\n

Quick Assessment <\/p>\n

\u2705 Price vs Analyst Target: Novo Nordisk shares at DKK280.4 sit about 10% below the DKK311.8 analyst target.<\/p>\n

\u2705 Simply Wall St Valuation: The stock is flagged as trading 57.2% below an internal fair value estimate.<\/p>\n

\u274c Recent Momentum: The share price has fallen 6.3% over the past 30 days.<\/p>\n

There’s only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value<\/a>.<\/p>\n

Key Considerations <\/p>\n

\ud83d\udcca China approval for oral Wegovy would expand Novo Nordisk’s obesity reach into a large market and add another route of administration on top of injectables.<\/p>\n

\ud83d\udcca Watch Chinese regulatory milestones, prescription trends for oral versus injectable obesity treatments, and how pricing compares with existing therapies.<\/p>\n

\u26a0\ufe0f Key risks include execution in China, higher debt and a dividend not fully covered by free cash flow, alongside four identified company risks overall.<\/p>\n

Dig Deeper <\/p>\n

For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis<\/a>. Alternatively, you can check out the community page for Novo Nordisk<\/a> to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":109443,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[55373,174,272,18580,10593,1470],"class_list":["post-109442","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-central-obesity","tag-china","tag-novo-nordisk","tag-oral-treatments","tag-regulatory-approval","tag-simply-wall-st"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116761882032285622","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/109442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=109442"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/109442\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/109443"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=109442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=109442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=109442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}